MyRenalCare

NHS Problem

Chronic kidney disease (CKD) affects 10% of the population in the UK (> 6 million people) and the majority don’t know they have it. It is underdiagnosed, and many of those who are diagnosed receive sub-optimal care due to a lack of kidney specialists.  In its late stages, CKD has an enormous impact on the quality of life for patients, their families, and carers, as well as significant emotional and financial burdens. Treatment of CKD costs the NHS more than £6.4bn every year, and this is projected to grow to 14 billion by 2030 if things do not change.  

The Solution

MyRenalCare transforms CKD diagnosis and management using digital health and point of care (POC) testing. POC testing can take place in the community, making it easier for individuals to be diagnosed. The MyRenalCare digital health platform replaces traditional face-to-face appointments with data-driven, remote, 100% digital appointments, whilst providing education to patients and access to their kidney specialists. The result is individuals who have a better understanding of their condition and are more engaged and empowered. For the NHS MyRenalCare significantly increases capacity for both diagnosis and management of CKD at considerably lower costs. 

Impact

MyRenalCare has been used by over 2000 patients and has delivered over 3000 virtual consultations saving 500 hours of clinician and patient time. Independent health economics has shown that MyRenalCare increases outpatient clinic capacity by 33% whilst reducing costs by 25%, the equivalent of £1.5m for Portsmouth Hospital University NHS Trust per year. 94% of patients recommend MyRenalCare and 89% prefer it to standard care. In addition, independent environmental analysis by the University of Manchester has shown that MyRenalCare remote follow-up appointments reduce the carbon emissions per patient versus face-to-face appointments by over 80% due to less patient travel.